Celgene Corporation / Gloucester Pharmaceuticals, Inc.
2009 · Acquisition/Merger · $640M · Complete
Announcement Sentiment
92
Strongly positive
Celgene acquired Gloucester Pharmaceuticals for $340M in cash plus up to $300M in regulatory milestone payments (approximately $640M total). The deal gave Celgene romidepsin (Istodax), an HDAC-inhibitor approved for cutaneous T-cell lymphoma, strengthening its hematology-oncology portfolio.